AR068381A1 - Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 - Google Patents
Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6Info
- Publication number
- AR068381A1 AR068381A1 ARP080103894A ARP080103894A AR068381A1 AR 068381 A1 AR068381 A1 AR 068381A1 AR P080103894 A ARP080103894 A AR P080103894A AR P080103894 A ARP080103894 A AR P080103894A AR 068381 A1 AR068381 A1 AR 068381A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- haloalkoxy
- radicals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de quinolina, los cuales poseen propiedades terapéuticas valiosas y son apropiados, en particular, para tratar enfermedades que responden a la modulacion del receptor de serotonina 5-HT6. Se proveen además composiciones farmacéuticas que los comprenden. Reivindicacion 1: Compuestos quinolina caracterizados porque responden a la formula (1) en donde R es una porcion de formula (2) en donde A es una union química, CHR5 o CH2CHR5; R1 es hidrogeno, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 o haloalcoxi C1-4; R2 es hidrogeno, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 o haloalcoxi C1-4; R3 es H o alquilo C1-4; R1 y R3 juntos también pueden ser alquileno C1-4 lineal, el cual puede contener 1 o 2 radicales R6; R4 es hidrogeno, alquilo C1-6, hidroxialquilo C1-6, haloalquilo C1-6, alcoxi C1-6-alquilo C1-4, haloalcoxi C1-6-alquilo C1-4, cicloalquilo C3-6, halo-cicloalquilo C3-6, cicloalquil C3-6-aIquiIo C1-4, aril-C1-4-alquilo, hetaril-C1-4-alquilo, alquenilo C3-6, haloalquenilo C3-6, formilo, alquilcarbonilo C1-4 o alcoxicarbonilo C1-4; R5 es hidrogeno, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 o haloalcoxi C1-4; R1 y R5 juntos también pueden ser una union simple, alquileno C1-4 lineal, el cual puede contener 1 o 2 radicales R7; o R3 y R5 juntos también pueden ser alquileno C1-4 lineal, el cual puede contener 1 o 2 radicales R8; R6 es alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 o haloalcoxi C1-4; o R5 y R6 juntos también pueden ser alquileno C1-4 lineal, el cual puede contener 1 o 2 radicales R9; R7, R8 y R9 se seleccionan en forma independiente entre el grupo que consiste de alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 y haloalcoxi C1-4; n es 0,1 o 2; m es 0,1, 2 o 3; Ra, Rb se seleccionan en forma independiente entre el grupo que consiste de halogeno, CN, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, C(O)Raa, C(O)NRccRbb y NRccRbb; en donde Raa es hidrogeno, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 o haloalcoxi C1-4, y Rcc, Rbb se seleccionan en forma independiente entre el grupo que consiste de hidrogeno y alquilo C1-4; X es CH2, C(O), S, S(O) o S(O)2; el cual se encuentra en la posicion 3 o 4 del anillo quinolina; Ar es un radical Ar1, Ar2-Ar3 o Ar2-O-Ar3, en donde Ar1, Ar2 y Ar3 se selecciona cada uno en forma independiente entre el grupo que consiste de arilo o hetarilo en donde las porciones arilo o hetarilo pueden ser no sustituidas o pueden contener 1 2, 3 sustituyentes Rx, en donde Rx es halogeno, CN, NO2, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6-alquilo C1-4, alquenilo C2-6, haloalquenilo C2-6, cicloalquilo C3-6, halocicloalquilo C3-6, alcoxi C1-6, hidroxi-alcoxi C1-6, alcoxi C1-6-alcoxi C1-4, haloalcoxi C1-6, alquiltio C1-6, haloalquiltio C1-6, alquilsulfinilo C1-6, haloalquilsulfinilo C1-6, alquilsulfonilo C1-6, haloalquilsulfonilo C1-6, alquilcarbonilo C1-6, haloalquil-carbonilo C1-6, alquilcarbonil-amino C1-6, haloalquil-carbonilamino C1-6, carboxi, NH-C(O)NRx1Rx2, NRx1Rx2, NRx1Rx2-alquileno C1-6, O-NRx1Rx2, en donde Rx1 y Rx2 en los ultimos 4 radicales mencionados son en forma independiente entre sí hidrogeno, alquilo C1-6, haloalquilo C1-6 o alcoxi C1-6 o Rx1 y Rx2 en los ultimos 4 radicales mencionados junto con el átomo de nitrogeno forman un heterociclo saturado de 5, 6 o 7 miembros unido a N el cual no se sustituye o contiene 1, 2, 3 o 4 radicales seleccionados entre alquilo C1-4, haloalquilo C1-4, hidroxialquilo C1-4 y alcoxi C1-4 y en donde 2 radicales Rx, los cuales se encuentran unidos a átomos de carbono adyacentes de Ar pueden formar un anillo carbocíclico o heterocíclico de 5 o 6 miembros saturado o insaturado, el cual en sí mismo puede contener un radical Rx; con la salvedad de que siendo X S(O)2 al menos uno de los radicales R1, R2 y si se encuentra presente R5 difiere de hidrogeno y alquilo C1-4; y sales de adicion ácida fisiologicamente tolerados y los N-oxidos de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104806 | 2007-03-23 | ||
| PCT/EP2008/053387 WO2008116831A1 (en) | 2007-03-23 | 2008-03-20 | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068381A1 true AR068381A1 (es) | 2009-11-11 |
Family
ID=39620293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103894A AR068381A1 (es) | 2007-03-23 | 2008-09-08 | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8242102B2 (es) |
| EP (1) | EP2139880B1 (es) |
| JP (1) | JP5538907B2 (es) |
| KR (1) | KR20090128426A (es) |
| CN (1) | CN101679351B (es) |
| AR (1) | AR068381A1 (es) |
| AT (1) | ATE524456T1 (es) |
| AU (1) | AU2008231787A1 (es) |
| BR (1) | BRPI0809081A2 (es) |
| CA (1) | CA2681030C (es) |
| CO (1) | CO6230989A2 (es) |
| CR (1) | CR11039A (es) |
| DO (1) | DOP2009000228A (es) |
| EC (1) | ECSP099651A (es) |
| ES (1) | ES2373617T3 (es) |
| HK (1) | HK1139933A1 (es) |
| IL (1) | IL201105A0 (es) |
| MX (1) | MX2009010243A (es) |
| NZ (1) | NZ579735A (es) |
| PE (1) | PE20091187A1 (es) |
| RU (1) | RU2009139073A (es) |
| TW (1) | TW200940524A (es) |
| UA (1) | UA97837C2 (es) |
| UY (1) | UY31326A (es) |
| WO (1) | WO2008116831A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130343993A1 (en) * | 2012-01-06 | 2013-12-26 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| AR106515A1 (es) | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
| WO2017157929A1 (en) * | 2016-03-14 | 2017-09-21 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| CN109503449A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3477466B2 (ja) * | 1999-09-02 | 2003-12-10 | 湧永製薬株式会社 | キノリンカルボン酸誘導体又はその塩 |
| JP2003277416A (ja) | 2002-03-22 | 2003-10-02 | Daiyanitorikkusu Kk | 糖類を含むアクリルアミド水溶液 |
| DK1497266T3 (da) * | 2002-03-27 | 2008-10-06 | Glaxo Group Ltd | Quinolinderivater og deres anvendelse som 5HT6-ligander |
| AU2002243097A1 (en) | 2002-04-03 | 2003-10-13 | Hyundai Pharm. Ind. Co., Ltd. | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
| EP1513809A1 (en) | 2002-06-05 | 2005-03-16 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
| GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| WO2007025798A2 (en) | 2005-07-27 | 2007-03-08 | F. Hoffmann-La Roche Ag | 4-aryloxy quinoline derivatives as 5-ht6 modulators |
| GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| EP2120950B1 (en) | 2007-03-21 | 2012-07-04 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain |
-
2008
- 2008-03-20 CN CN200880017192.XA patent/CN101679351B/zh not_active Expired - Fee Related
- 2008-03-20 MX MX2009010243A patent/MX2009010243A/es active IP Right Grant
- 2008-03-20 AU AU2008231787A patent/AU2008231787A1/en not_active Abandoned
- 2008-03-20 ES ES08735447T patent/ES2373617T3/es active Active
- 2008-03-20 CA CA2681030A patent/CA2681030C/en not_active Expired - Fee Related
- 2008-03-20 EP EP08735447A patent/EP2139880B1/en active Active
- 2008-03-20 JP JP2009554034A patent/JP5538907B2/ja not_active Expired - Fee Related
- 2008-03-20 RU RU2009139073/04A patent/RU2009139073A/ru not_active Application Discontinuation
- 2008-03-20 NZ NZ579735A patent/NZ579735A/en not_active IP Right Cessation
- 2008-03-20 BR BRPI0809081A patent/BRPI0809081A2/pt not_active IP Right Cessation
- 2008-03-20 AT AT08735447T patent/ATE524456T1/de not_active IP Right Cessation
- 2008-03-20 KR KR1020097019918A patent/KR20090128426A/ko not_active Application Discontinuation
- 2008-03-20 UA UAA200910698A patent/UA97837C2/ru unknown
- 2008-03-20 WO PCT/EP2008/053387 patent/WO2008116831A1/en active Application Filing
- 2008-03-23 US US12/532,407 patent/US8242102B2/en not_active Expired - Fee Related
- 2008-09-02 TW TW097133636A patent/TW200940524A/zh unknown
- 2008-09-08 AR ARP080103894A patent/AR068381A1/es not_active Application Discontinuation
- 2008-09-08 PE PE2008001568A patent/PE20091187A1/es not_active Application Discontinuation
- 2008-09-08 UY UY0001031326A patent/UY31326A/es not_active Application Discontinuation
-
2009
- 2009-09-22 IL IL201105A patent/IL201105A0/en unknown
- 2009-09-22 DO DO2009000228A patent/DOP2009000228A/es unknown
- 2009-09-22 CO CO09103181A patent/CO6230989A2/es not_active Application Discontinuation
- 2009-09-23 CR CR11039A patent/CR11039A/es unknown
- 2009-09-23 EC EC2009009651A patent/ECSP099651A/es unknown
-
2010
- 2010-07-02 HK HK10106465.1A patent/HK1139933A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009139073A (ru) | 2011-04-27 |
| CR11039A (es) | 2010-02-09 |
| UY31326A (es) | 2009-11-10 |
| WO2008116831A1 (en) | 2008-10-02 |
| UA97837C2 (ru) | 2012-03-26 |
| HK1139933A1 (en) | 2010-09-30 |
| ES2373617T3 (es) | 2012-02-07 |
| CA2681030A1 (en) | 2008-10-02 |
| PE20091187A1 (es) | 2009-09-06 |
| EP2139880A1 (en) | 2010-01-06 |
| ATE524456T1 (de) | 2011-09-15 |
| US20110009380A1 (en) | 2011-01-13 |
| MX2009010243A (es) | 2009-12-14 |
| AU2008231787A1 (en) | 2008-10-02 |
| DOP2009000228A (es) | 2009-10-15 |
| TW200940524A (en) | 2009-10-01 |
| CA2681030C (en) | 2015-01-13 |
| US8242102B2 (en) | 2012-08-14 |
| ECSP099651A (es) | 2009-10-30 |
| EP2139880B1 (en) | 2011-09-14 |
| KR20090128426A (ko) | 2009-12-15 |
| JP2010521520A (ja) | 2010-06-24 |
| BRPI0809081A2 (pt) | 2019-09-24 |
| JP5538907B2 (ja) | 2014-07-02 |
| CN101679351A (zh) | 2010-03-24 |
| CN101679351B (zh) | 2015-01-07 |
| IL201105A0 (en) | 2010-05-17 |
| NZ579735A (en) | 2012-02-24 |
| CO6230989A2 (es) | 2010-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| AR077892A1 (es) | Quinolinas antagonistas de la hepcidina | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR054813A1 (es) | Derivados de pirroloquinolinas y sus usos como inhibidores de proteinas quinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |